Speaker
Rolf Hilgenfeld
Description
Structure-based design of new inhibitors of the SARS-CoV-2 main protease (Mpro) is discussed and corresponding crystal structures are described. Pharmacokinetics of frontrunner inhibitors are presented. The evolution of the Mpro from the original Wuhan strain via the Alpha, Beta, Delta, and Omicron variants of concern is followed in terms of three-dimensional (crystal) structures, enzymatic activities, and inhibitor potencies.
Primary authors
Dr
Haifa El Kilani
(University of Lübeck)
Mrs
Judith Röske
(University of Lübeck)
Mrs
Kaixuan Zhang
(University of Lübeck)
Dr
Katharina Rox
(Helmholtz Centre for Infection Research)
Dr
Linlin Zhang
(University of Lübeck)
Prof.
Mark Brönstrup
(Helmholtz Centre for Infection Research)
Dr
Matthias Göhl
(Helmholtz Centre for Infection Research)
Dr
Ravikumar Akula
(University of Lübeck)
Rolf Hilgenfeld
Mrs
Xinyuanyuan Sun
(University of Lübeck)
Dr
Yuri Kusov
(University of Lübeck)
